Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

The latest GeneSight ® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reveals that Americans ...
Nasdaq

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
News Medical

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Seeking Alpha

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Business Insider

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
Seeking Alpha

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
News Medical

GeneSight test improves outcomes in major depressive disorder, meta-analysis shows

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...